Abstract：
To evaluate the efficacy and safety of different Chinese patent medicines in the treatment of pelvic inflammatory disease(PID) using network Meta-analysis. The databases of CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library, EMbase, and Web of Science were searched, and from the time of database construction to July 16, 2023, the randomized controlled trial(RCT) of Chinese patent medicines combined with antibiotics in the treatment of PID included in these databases was collected. The quality of the included literature was evaluated using the Cochrane risk of bias tool, and data was analyzed using RevMan 5.4 and Stata 16 software. Forty-six RCTs were finally included, including Kangfu Xiaoyan Suppositories, Fuke Qianjin Tablets/Capsules, Kangfuyan Capsules, Fuyanxiao Capsules, Huahong Tablets/Capsules, Fuyanshu Capsules, Fuyue Tablets, Jingangteng Capsules, and Fuyan Kangfu Capsules. Network Meta-analysis showed that,(1) in terms of clinical effective rate, the optimal intervention was Kangfu Xiaoyan Suppositories combined with antibiotics.(2) In terms of lowering hypersensitive C-reactive protein(hs-CRP), the optimal intervention was Huahong Tablets/Capsules combined with antibiotics.(3) In terms of lowering tumor necrosis factor-α(TNF-α), the optimal intervention was Fuyue Tablets combined with antibiotics.(4) In terms of lowering recurrence rate, the optimal intervention was Fuyanshu Capsules combined with antibiotics.(5) In terms of safety, the intervention with the least adverse reactions was Kangfuyan Capsules combined with antibiotics. The results show that Chinese patent medicines combined with antibiotics in the treatment of PID can improve the comprehensive efficacy, reduce the patient\'s hs-CRP and TNF-α, and have a low recurrence rate, as well as safe and reliable efficacy. In clinical treatment, Kangfu Xiaoyan Suppositories or Kangfuyan Capsules combined with antibiotics can be preferred. Due to the limitations of the sample size and the quality of the literature, more large-sample and high-quality studies are needed to validate the conclusions.
摘要：
采用网络Meta分析评价不同中成药治疗盆腔炎的有效性和安全性。CNKI的数据库，万方,VIP,SinoMed,PubMed,科克伦图书馆,EMBase,搜索了科学网，并收集了从数据库构建到2023年7月16日的中成药联合抗生素治疗PID的随机对照试验(RCT)。使用Cochrane偏差风险工具评估纳入文献的质量，数据采用RevMan5.4和Stata16软件进行分析。46个RCT最终被包括在内，包括康妇消炎栓，妇科千金片/胶囊，康福炎胶囊,妇炎消胶囊,华红片/胶囊，妇炎舒胶囊,复月片,金刚腾胶囊，和妇炎康福胶囊。网络荟萃分析表明,(1)在临床有效率方面,最佳干预措施为康妇消炎栓联合抗生素。(2)在降低超敏C反应蛋白(hs-CRP)方面,最佳干预措施为华红片/胶囊联合抗生素。（3）在降低肿瘤坏死因子-α（TNF-α）方面，最佳干预措施为复月片联合抗生素。（4）在降低复发率方面，最佳干预措施为妇炎舒胶囊联合抗生素。（5）在安全方面，不良反应最少的干预措施是康妇炎胶囊联合抗生素。结果表明,中成药联合抗生素治疗PID可提高综合疗效,降低患者的hs-CRP和TNF-α，复发率低，以及安全可靠的疗效。在临床治疗中,康妇消炎栓或康妇炎胶囊联合抗生素可作为首选。由于样本量和文献质量的限制，需要更多的大样本和高质量的研究来验证结论。
